Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Intel Corp (INTC) Price & Performance

Gilead Sciences, Inc.Trade
Intel CorpTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Intel Corp — how do they compare? Gilead Sciences, Inc. trades at $135.67 (market cap $164.99B), while Intel Corp trades at $99.77 (market cap $491.89B). The key difference: Intel Corp is far larger — about 3× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.

GILDINTC
Market Cap
$164.99B$491.89B
Sector
HealthTechnology
52-Week High
$155.80$140.94
52-Week Low
$110.56$21.81
Enterprise Value
$188.06B$512.70B
Dividend Yield
2.47%2.24%
Volume
43,552,012

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Intel Corp

Intel (INTC) trades at $101.65, up 1.84% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $267 million in 2025 despite revenue of $52.85 billion, though it beat EPS estimates in recent quarters. Recent news highlights a $20 billion stock offering to fund AI expansion, causing short-term volatility but viewed as strategic for long-term growth.

Outlook is mixed: analyst consensus price target of $116.67 suggests upside, supported by AI investments, but high P/E of 904.17 and negative profit margins pose valuation risks. Key risks include intense competition, execution challenges in foundry growth, and reliance on capital raises amid cash burn in strategic segments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Intel Corp

Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.

Read more on INTC